PDF herunterladen
Z Gastroenterol 2014; 52(7): 749-756
DOI: 10.1055/s-0033-1362589
Mitteilungen der DGVS
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Empfehlung der DGVS und des bng zur Therapie der chronischen Hepatitis C

Christoph Sarrazin
1   Universitätsklinikum Frankfurt am Main, Med. Klinik 1, Frankfurt am Main
,
Thomas Berg
2   Sektion Hepatologie, Klinik für Gastroenterologie und Rheumatologie, Universitätsklinikum Leipzig
,
Peter Buggisch
3   Leberzentrum Hamburg im IFI an der Askleopios Klinik St. Georg, Hamburg
,
Matthias Dollinger
4   Universitätsklinikum Ulm
,
Holger Hinrichsen
5   Gastroenterologisch- Hepatologisches Zentrum Kiel
,
Dietrich Hüppe
6   Gastroenterologische Gemeinschaftspraxis Herne
,
Michael Manns
7   Medizinische Hochschule Hannover
,
Stefan Mauss
8   Zentrum für HIV und Hepatogastroenterologie, Düsseldorf
,
Jörg Petersen
3   Leberzentrum Hamburg im IFI an der Askleopios Klinik St. Georg, Hamburg
,
Karl-Georg Simon
9   MVZ für Gastroenterologie und Hepatologie, Leverkusen
,
Heiner Wedemeyer
7   Medizinische Hochschule Hannover
,
Stefan Zeuzem
1   Universitätsklinikum Frankfurt am Main, Med. Klinik 1, Frankfurt am Main
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. Juli 2014 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Interessenskonflikte:

Christoph Sarrazin: Vortrags- bzw. Beratungshonorare von Abbott, Abbvie, BMS, Boehringer-Ingelheim, Gilead, Janssen, Merck / MSD, Roche, Vertex. Klinische Studien bzw. Forschungsunterstützung von Abbott, Boehringer-Ingelheim, Gilead, Janssen, Qiagen, Roche, Siemens.

Thomas Berg: Vortrags- bzw. Beratungshonorare von Abbvie, BMS, Boehringer-Ingelheim, Gilead, Janssen, Novartis, Merck / MSD, Roche, Vertex. Klinische Studien bzw. Forschungsunterstützung von Abbvie, BMS, Boehringer-Ingelheim, Gilead, Janssen, Merck / MSD, Novartis, Roche, Vertex.

Peter Buggisch: Vortrags- bzw. Beratungshonorare von Abbvie, BMS, Boehringer-Ingelheim, Gilead, Janssen, Novartis, Merck / MSD, Roche, Vertex. Klinische Studien von Abbvie, BMS, Gilead, Janssen, Merck / MSD, Novartis, Roche, Siemens, Vertex.

Matthias Dollinger: Vortrags- bzw. Beratungshonorare von Bayer, BMS, Falk, Gore, Roche. Klinische Studien bzw. Forschungsunterstützung von Bayer, Novartis, Roche.

Holger Hinrichsen: Vortrags- und Beratungshonorare von Abbvie, BMS, Boehringer-Ingelheim, Gilead, Janssen, MSD, Roche.

Dietrich Hüppe: Vortrags- bzw. Beratungshonorare von MSD, Janssen, Roche, BMS, Boehringer-Ingelheim, Novartis, Abbvie, Gilead, Falk.

Michael Manns: Vortrags- bzw. Beratungshonorare von BMS, Boehringer-Ingelheim, Gilead, GlaxoSmithKline, Idenix, Janssen, Merck, Novartis, Roche. Klinische Studien und Forschungsunterstützung von BMS, Boehringer-Ingelheim, Gilead, Janssen, Merck, Novartis, Roche.

Stefan Mauss: Vortrags- und Beratungshonorare von Abbvie, Boehringer-Ingelheim, BMS, Gilead, Janssen, MSD, Roche.

Jörg Petersen: Vortrags- bzw. Beratungshonorare von Abbott, Abbvie, BMS, Boehringer, Gilead, GSK, Kedrion, Janssen, Merck, MSD, Novartis, Roche. Forschungsunterstützung von BMS, Novartis, Roche.

Karl-Georg Simon: Vortrags- bzw. Beratungshonorare von Abbvie, Boehringer-Ingelheim, BMS, Falk, Gilead, Janssen, Norgine, MSD, Roche.

Heiner Wedemeyer: Vortrags- bzw. Beratungshonorare von Abbott, Abbvie, Achillon, BMS, Boehringer-Ingelheim, Gilead, Janssen, MSD-Merck, Novartis, Roche, Siemens. Forschungsunterstützung von Abbott, Gilead, Janssen, Novartis, Roche.

Stefan Zeuzem: Vortrags- bzw. Beratungshonorare von Abbvie, BMS, Boehringer-Ingelheim, Gilead, Idenix, Janssen, Merck / MSD, Novartis, Roche, Santaris, Vertex. Durchführung klinischer Studien mit Abbvie, BMS, Boehringer-Ingelheim, Gilead, Janssen, Merck / MSD, Novartis, Roche, Santaris, Vertex.

 

  • Referenzen

  • 1 Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887
    CrossrefPubMedSuche in Google Scholar
  • 2 Kowdley KV, Lawitz E, Crespo I et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107
    CrossrefPubMedSuche in Google Scholar
  • 3 Pol S, Sulkowski M, Hassanein T et al. Successful retreatment with sofosbuvir of HCV genotype-1 infected patients who failed prior therapy with peginterferon and ribavirin plus 1 or 2 additional direct-acting antiviral agents. Journal of Hepatology 2014; 60: S23-S23
    PubMedSuche in Google Scholar
  • 4 Lawitz E, Poordad F, Brainard D et al. Sofosbuvir in combination with PEG-IFN and ribavirin for 12 weeks provides high SVR rates in HCV infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the Lonestar-2 study. Hepatology 2013; 58: LB-4
    PubMedSuche in Google Scholar
  • 5 Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221
    CrossrefPubMedSuche in Google Scholar
  • 6 Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493
    CrossrefPubMedSuche in Google Scholar
  • 7 Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44
    CrossrefPubMedSuche in Google Scholar
  • 8 Osinusi A, Meissner EG, Lee YJ et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-811
    CrossrefPubMedSuche in Google Scholar
  • 9 Lalezari JP, Nelson DR, Hyland RH et al. Once Daily Sofosbuvir Plus Ribavirin for 12 and 24 Weeks in Treatment-Naive Patients with Hcv Infection: the Quantum Study. Journal of Hepatology 2013; 58: S346-S346
    PubMedSuche in Google Scholar
  • 10 Forns X, Lawitz E, Zeuzem S et al. Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial. Gastroenterology 2014;
    PubMedSuche in Google Scholar
  • 11 Manns M, Marcellin P, Poordad F et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;
    PubMedSuche in Google Scholar
  • 12 Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;
    PubMedSuche in Google Scholar
  • 13 Vermehren J, Aghemo A, Falconer K et al. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J Hepatol 2014; 60: 913-919
    CrossrefPubMedSuche in Google Scholar
  • 14 Reddy K, Zeuzem S, Zoulim F et al. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study. Hepatol Int 2014; 8: S397
    PubMedSuche in Google Scholar
  • 15 Lawitz E, Ghalib R, Rodriguez-Torres M et al. Simeprevir plus sofosbuvir with / without ribavirin in HCV genotype 1 prior null-responder / treatment-naive patients (Cosmos study): primary endpoint (SVR12) results in patients with metavir F3–4 (Cohort 2). Journal of Hepatology 2014; 60: S524-S524
    PubMedSuche in Google Scholar
  • 16 Sulkowski M, Jacobson IM, Ghalib R et al. Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with metavir F0–2: Cosmos study subgroup analysis. Journal of Hepatology 2014; 60: S4
    PubMedSuche in Google Scholar
  • 17 Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011; 364: 2405-2416
    CrossrefPubMedSuche in Google Scholar
  • 18 Bacon BR, Poordad F, McCone Jr. J et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206
    CrossrefPubMedSuche in Google Scholar
  • 19 Sarrazin C, Schwendy S, Müller B et al. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24–72 weeks. Gastroenterology 2011; epub.
    PubMedSuche in Google Scholar
  • 20 Sarrazin C, Berg T, Ross RS et al. Update der S3-Leitlinie Prophylaxe, Diagnose und Therapie der Hepatitis C Virus (HCV) Infektion. Z Gastroenterol 2010; 48: 289-351
    Suche in Google Scholar
  • 21 Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877
    CrossrefPubMedSuche in Google Scholar
  • 22 Lawitz E, Lalezari JP, Hassanein T et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-408
    CrossrefPubMedSuche in Google Scholar
  • 23 Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001
    CrossrefPubMedSuche in Google Scholar
  • 24 Ruane PJ, Ain D, Meshrekey R et al. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naive and treatment-experienced patients with chronic genotype 4 HCV infection. Journal of Hepatology 2014; 60: S503-S504
    PubMedSuche in Google Scholar
  • 25 Moreno C, Hezode C, Marcellin P et al. Once-daily simeprevir (TMC435) with peginterferon / ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase III trial. Journal of Hepatology 2014; 60: S535-S535
    PubMedSuche in Google Scholar
  • 26 Lenz O, Vijgen L, Berke JM et al. Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 2013; 58: 445-451
    CrossrefPubMedSuche in Google Scholar
  • 27 Sulkowski MS, Rodriguez-Torres M, Lalezari J et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (Photon-1). Hepatology 2013; 58: 313A
    CrossrefPubMedSuche in Google Scholar
  • 28 Rodriguez-Torres M, Rodriguez-Orengo J, Gaggar A et al. Sofosbuvir and peginterferon alfa-2a / ribavirin for treatment-naive genotype 1–4 HCV-infected patients who are coinfected with HIV. Infectious Disease Week 2014: Abstract 2014.
    PubMed
  • 29 Curry MP, Forns X, Chung R et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013; 58: 314A
    PubMedSuche in Google Scholar
  • 30 Charlton M, Gane E, Manns MP et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infeciton after liver transplantation: preliminary results of a prospective, multicenter study. Hepatology 2013; 58: LB-2
    PubMedSuche in Google Scholar